|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Normalization of ejec-tion fraction and resolution of symptoms in chronic severe heart failureis possible with modern medical therapy:clinical observations in11patients显示文摘 | Harinstein M E Berlier J I Shah S J | 2008 | A m J Ther2008，15，： | 1 |
| 2 | Cardiovascular Risk Assessment of the Liver Transplant Candidate显示文摘 | Zankhana Raval Matthew E. Harinstein Anton I. Skaro Ata Erdogan Andre M. DeWolf Sanjiv J. Shah Oren K. Fix Nina Kay Michael I. Abecassis Mihai Gheorghiade James D. Flaherty | 2011 | Journal of the American College of Cardiology2011，，3： | 1 |
| 3 | Digoxin for the treatment of chronic and acute heart failure syn- dromes显示文摘 | Gheorghiade M Harinstein ME Filippatos GS | 2009 | Acute Cardiac care2009，11，2： | 1 |
| 4 | Acute heart failure syndromes: Epidemiology, risk stratification and prognostic factors显示文摘 | Matthew E. Harinstein Gerasimos S. Filippatos Mihai Gheorghiade | 2009 | Acute Cardiac Care2009，，2： | 1 |
| 5 | Normalization of ejection fraction and resolution of symptoms in chronic severe heart failure is possible with modern medical therapy: clinical observations in 11 patients显示文摘 | HARINSTEIN M E BERLINER J I SHAH S J | 2008 | AmJ Ther2008，15，： | 1 |
| 6 | Acute heart failuresyndmmes : epidemiology7, risk stratification and prognostic factors显示文摘 | Harinstein ME Filippatos GS Gheorghiadc M | 2013 | Acute Card Care2013，11，2： | 1 |
| 7 | Digoxin for the treatment of chronic and acute heart failure syndromes 显示文摘 | Gheorghiade M Harinstein ME Filippatos GS | 2009 | Acute Card Care2009，11，2： | 1 |
| 8 | Use of an abnormal laboratory value - drug combination alert to detect drug - induced thrombocytopenia in critically ill patients显示文摘 | Harinstein LM Kane- Gill SL Smithburger PL | 2012 | J Cric Care2012，27，： | 1 |
| 9 | Cardiovascular risk assessment of the liver transplant candidate显示文摘 | Raval Z Harinstein ME Skaro AI | | 0，，03： | 1 |
| 10 | Cardiovascular risk as sessment of the liver transplant candidate显示文摘 | Raval Z Harinstein M E Skaro A I | 2011 | J Am Coil Cm''diol2011，58，3： | 1 |
| 11 | Cardiovascular Risk Assessment of the Liver Transplant Candidate显示文摘 | Zankhana Raval Matthew E. Harinstein Anton I. Skaro Ata Erdogan Andre M. DeWolf Sanjiv J. Shah Oren K. Fix Nina Kay Michael I. Abecassis Mihai Gheorghiade James D. Flaherty | 2011 | Journal of the American College of Cardiology2011，，3： | 1 |
| 12 | Digoxin for the treatment of chronic and acute heart failure syndromes显示文摘 | Mihai Gheorghiade Matthew E. Harinstein Gerasimos S. Filippatos | 2009 | Acute Cardiac Care2009，，2： | 1 |
| 13 | Role of cardiovascular intervention as a bridge to liver transplantation显示文摘End stage liver disease(ESLD) is associated with many specific derangements in cardiovascular physiology, which influence perioperative outcomes and may pro-foundly influence diagnostic and management strate-gies in the preoperative period. This review focuses on evidence-based diagnosis and management of coro-nary, hemodynamic and pulmonary vascular disease in this population with an emphasis on specific strategies that may provide a bridge to transplantation. Specifi-cally, we address the underlying prevalence of cardio-vascular disease states in the ESLD population, and relevant diagnostic criteria thereof. We highlight tradi-tional and non-traditional predictors of cardiovascular outcomes following liver transplant, as well as data to guide risk-factor based diagnostic strategies. We go on to discuss the alterations in cardiovascular physiology which influence positive- and negative-predictive values of standard noninvasive testing modalities in the ESLD population, and review the data regarding the safetyand efficacy of invasive testing in the face of ESLD and its co-morbidities. Finally, based upon the totality of available data, we outline an evidence-based ap-proach for the management of ischemia, heart failure and pulmonary vascular disease in this population. It is our hope that such evidence-driven strategies can be employed to more safely bridge appropriate candidates to liver transplant, and to improve their cardiovascular health and outcomes in the peri-operative period. | Zankhana Raval Matthew E Harinstein James D Flaherty | 2014 | World Journal of Gastroenterology2014，20，31： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员